RFCA
CNCE

R&F Capital Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

R&F Capital Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$273K Buy
+15,991
New +$192K 0.07% 441

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

R&F Capital Advisors's CNCE Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017: 15,991 shares worth $273K. The stake represents 0.07% of the portfolio and ranks #441 among its holdings.

85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

  • R&F Capital Advisors held 15,991 shares of Concert Pharmaceuticals, Inc. worth $273K as of Q1 2017.
  • Concert Pharmaceuticals, Inc. was a new R&F Capital Advisors position in Q1 2017.
  • Concert Pharmaceuticals, Inc. made up 0.07% of R&F Capital Advisors's portfolio in Q1 2017, its #441 holding.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.